Terlipressin - BioVie

Drug Profile

Terlipressin - BioVie

Alternative Names: BIV-201; Glycylpressin; Glypressin; Terlipressin acetate continuous infusion

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioVie
  • Developer Assiut University; BioVie
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ascites; Haemorrhage

Most Recent Events

  • 09 Apr 2018 BioVie completes 50% enrolment in its phase IIa trial for Ascites in USA
  • 11 Dec 2017 Terlipressin - BioVie receives Fast Track designation for Ascites [IV,Infusion] (Treatment-experienced) in USA
  • 25 Oct 2017 BioVie applies for Orphan drug designations for terlipressin for life-threatening indications associated with liver cirrhosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top